Sana Biotechnology Inc vs US Bancorp — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while US Bancorp trades at $63.14 (market cap $98.36B). The key difference: US Bancorp is far larger — about 112.6× Sana Biotechnology Inc's market cap, and US Bancorp pays a 3.29% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | USB | |
|---|---|---|
Market Cap | $873.84M | $98.36B |
Sector | Health | Financials |
52-Week High | $5.92 | $64.01 |
52-Week Low | $2.68 | $43.94 |
Enterprise Value | $848.03M | — |
Dividend Yield | — | 3.29% |
Trailing returns across standard periods
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →